Century Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$109M
R&D
$96M
D&A
$13M
Operating Income
$-17M
EBITDA
$-4M
Interest Expense
—
Other Income/Expense
$8M
Pretax Income
$-10M
Tax Provision
$-68K
Net Income
$-10M
Operating Margin
-15.8%
Net Margin
-8.8%
Effective Tax Rate
0.7%
Deferred Tax Assets
$11M
Deferred Tax Liabilities
$4M
DTA Valuation Allowance
$198M
Tax Credit Carryforwards
$23M
NOL Carryforwards
$109M
ETR (Continuing Operations)
0.7%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.8%
ETR Foreign Differential (pp)
0.1%
Operating Lease Cost
$7M
Revenue YoY Variation
1556.8%
Income YoY Variation
87.5%